BioPharma Resources

Drug Trial Radar · NCT06603142

Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia

A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase II/III Study to Evaluate the Efficacy and Safety of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia

Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 636 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

636

Planned (sponsor's estimate)

Start

Apr 22, 2024

Primary completion

Apr 2026

Study completion Apr 2026

Sponsor

Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the efficacy and safety of AR882 Capsules in patients with primary gout and hyperuricemia. The main questions it aims to answer are: What is the efficacy of AR882 Capsules in reducing serum uric acid levels in patients with primary gout and hyperuricemia? Researchers will compare AR882 Capsules with Febuxostat Tablets to see : Phase II: To explore the efficacy of AR882 Capsules in patients with primary gout and hyperuricemia, aiming to determine the dosing regimen for the Phase III study Phase III: To evaluate the efficacy of AR882 Capsules in patients with primary gout and hyperuricemia. Participants will: Be randomly assigned to receive either AR882 Capsules or Febuxostat Tablets. Undergo regular assessments of serum uric acid levels. Report any adverse events or side effects experienced during the study.

Conditions

  • Primary Gout
  • Hyperuricemia

Interventions

  • Febuxostat 20MG TabletsDrug

    Febuxostat 20MG Tablets

  • Febuxostat 20MG PlaceboDrug

    Febuxostat 20MG Placebo

  • AR882 25MGDrug

    AR882 25 MG Capsules

  • AR882 12.5MGDrug

    AR882 12.5 MG Capsules

  • AR882 25MG PlaceboDrug

    AR882 25MG Placebo

  • AR882 12.5MG PlaceboDrug

    AR882 12.5MG Placebo

  • Febuxostat 40MG TabletsDrug

    Febuxostat 40MG Tablets

  • Febuxostat 40MG PlaceboDrug

    Febuxostat 40MG Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage of participants with serum uric acid <360 μmol/LTime frame: 8 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital, Chinese Academy of Medical Science

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.